The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer
Published version of a preprint
Abstract
Purpose: For stage II colon cancer, the efficacy of postoperative adjuvant chemotherapy remains controversial. It is well known that tumor-associated macrophages (TAMs) are important in tumor progression. In this study, TAMs were investigated as prognostic and predictive biomarkers for the efficacy of adjuvant chemotherapy for stage II colon cancer after radical resection. Experimental Design: This study enrolled two independent cohorts of consecutive patients from one medical center with pathologic stage II colon cancer after radical resections. Macrophages were detected using IHC staining of CD68 and CD206. Infiltration densities of CD68+ TAMs, CD206+ TAMs, and ratio of CD206+ TAMs/CD68+ TAMs (CD206/CD68 ratio) were calculated as prognostic and predictive biomarkers. Results: The primary and validation cohorts consisted of 521 and 314 patients, respectively. In both cohorts, high CD206/CD68 ratio was significantly associated with poor disease-free survival (DFS) and overall survival (OS). As an independent risk factor, CD206/CD68 ratio also had significantly better prognostic efficacy than CD68+ TAM density, CD206+ TAM density, and traditional clinicopathologic high-risk factors. Moreover, adjuvant chemotherapy significantly improved DFS and OS for patients with high CD206/CD68 ratio but not for those with low CD206/CD68 ratio. The interaction analyses were also significant for DFS. In subgroup analysis, CD206/CD68 ratio was still a significant predictor for adjuvant chemotherapy for patients in traditional high-risk group of recurrence (significant interaction for DFS). Conclusions: For stage II colon cancer, CD206/CD68 ratio is a better prognostic and predictive biomarker for postoperative adjuvant chemotherapy. Together with clinicopathologic high-risk factors, it will aid in precision treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One instance of clinical data suggests that the M1/M2 ratio reflects the sensitivity of CRC patients to adjuvant therapy [328].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [328]
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Evaluating the Yield of Medical Tests
Harrell, F. E. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320430047030 · Cited by 3,490
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,695
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 2×
“It has been shown that patients in the low-risk group have a good prognosis and do not benefit from adjuvant chemotherapy (11, 12).”
BackgroundSargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 2×
“It has been shown that patients in the low-risk group have a good prognosis and do not benefit from adjuvant chemotherapy(11,12).”
BackgroundAdjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Direct Visualization of Macrophage-Assisted Tumor Cell Intravasation in Mammary Tumors
Wyckoff, J. B., Wang, Y., Lin, E. Y., Li, J.-F., Goswami, S., Stanley, E. R., Segall, J. E., Pollard, J. W., & Condeelis, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1823 · Cited by 1,053
Cited by
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers
Larionova, I., Tuguzbaeva, G., Ponomaryova, A., Stakheyeva, M., Cherdyntseva, N., Pavlov, V., Choinzonov, E., & Kzhyshkowska, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566511 · Cited by 392
Wang, H., Tian, T., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168470 · Cited by 364
The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment
Väyrynen, J. P., Haruki, K., Lau, M. C., Väyrynen, S. A., Zhong, R., Dias Costa, A., Borowsky, J., Zhao, M., Fujiyoshi, K., Arima, K., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0527 · Cited by 228
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
Pinto, M. L., Rios, E., Durães, C., Ribeiro, R., Machado, J. C., Mantovani, A., Barbosa, M. A., Carneiro, F., & Oliveira, M. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01875 · Cited by 213
Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 200
Metadata
- Authors
- Feng, Q., Chang, W., Mao, Y., He, G., Zheng, P., Tang, W., Wei, Y., Ren, L., Zhu, D., Ji, M., Tu, Y., Qin, X., & Xu, J.
- Affiliations
- Fudan University (CN)
- 174th hospital of the People's Liberation Army (CN)
- Corresponding author
- Qin, Xinyu
- Xu, Jianmin
- Venue
- Clinical Cancer Research
- Published
- 2019-07-01
- Volume
- 25
- Issue
- 13
- Pages
- 3896-3907
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2936067542
- Cited by
- 152
- References
- 41
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 15 · 2023: 30 · 2022: 32 · 2021: 32 · 2020: 21 · 2019: 3
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81602040, 81602035, 81472228)
- Science and Technology Project of Xiamen (3502Z20154040)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- tumor-associated macrophages, stage II colon cancer, adjuvant chemotherapy, prognostic factors, predictive biomarkers, CD68, CD206, disease-free survival, overall survival, radical resection, recurrence risk, precision therapy
- MeSH terms
- Colonic Neoplasms, Follow-Up Studies, Humans, Immunohistochemistry, Macrophages, Neoplasm Staging, Postoperative Care, Prognosis, Antigens, Differentiation, Myelomonocytic, Biomarkers, Immunophenotyping, Chemotherapy, Adjuvant, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-2076
- The paper
- Feng, Q., Chang, W., Mao, Y., He, G., Zheng, P., Tang, W., Wei, Y., Ren, L., Zhu, D., Ji, M., Tu, Y., Qin, X., & Xu, J. (2019). Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-2076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.